Congenital heart defects occur when the heart or blood vessels near the heart don’t develop normally before birth. Defects may be caused by chromosomal abnormalities, but the cause is unknown in most cases.
Researchers examined patterns of congenital heart defects incidence and presence of environmental toxicants in Alberta, Canada. The ongoing research seeks to determine if pregnant women’s proximity to organic compounds and metals emitted in the air impacts the risk of heart defects in their children.
“Although still in the early stage, this research suggests some chemical emissions — particularly, industrial air emissions — may be linked to heart abnormalities that develop while the heart is forming in the womb,” said lead researcher Deliwe P. Ngwezi, M.D., a Ph.D., student and research fellow in pediatric cardiology at the University of Alberta in Canada.
The study is based on congenital heart defects diagnosed in 2004-11 and chemical emissions recorded by a Canadian agency tracking pollutants.
Researchers looked at three chemical categories, but only one group showed a strong correlation with rates of congenital heart defects. According to Ngwezi, the group of chemicals consists of a mixture of organic compounds and metals namely: benzene, butadiene, carbon disulphide, chloroform, ethylene oxide, hexachlorobenzene, tetrachloroethane, methanol, sulphur dioxide, toluene, lead, mercury and cadmium.
Congenital heart defect rates have gradually decreased in Canada since 2006, which is about the time the government tightened regulations to reduce industrial air emissions, Ngwezi said. The heart defect decreases were mainly associated with heart defects resulting in holes between the upper and lower heart chambers (septal defects) and malformations of the cardiac outflow tracts (conotruncal defects), according to Ngwezi.
“For now, consumers and healthcare providers should be educated about the potential toll of pollutants on the developing heart,” she said. “As we have observed in the preliminary results, when the emissions decrease, the rates of congenital heart defects also decrease.”
This study, she said, should draw attention to the increasing evidence about the impact of environmental pollution on birth defects. Limitations of the study include that researchers’ observations were made at a group level, not according to individual risk and the self-reported industry data which is monitored and collected annually by government, according to Ngwezi.
Co-authors are Lisa K. Hornberger, M.D.; Brad Saretsky, B.Sc.; Sujata Chandra, M.D., M.Sc.; Deborah Fruitman, M.D., F.R.C.P.C.; and Alvaro Osornio-Vargas, M.D., Ph.D. Author disclosures are on the abstract.
The study was funded by the Women and Children’s Health Research Institute, University of Alberta; Hamilton-Naki Foundation of South Africa; and an Emerging Research Team Grant from the University of Alberta’s Faculty of Medicine and Dentistry and Alberta Health Services.
Note: Actual presentation time is from 3 p.m. CT/4 p.m. ET Sunday, Nov. 17, 2013.
Learn more about Congenital Heart Defects.
Downloadable video/audio interviews, B-roll, animation and images related to this news release are on the right column of the release link at
Video clips with researchers/authors of the studies will be added to the release link after embargo.
For more news from AHA Scientific Sessions 2013 follow us on Twitter @HeartNews #AHA13.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.